Opicapone

  • TRADE NAME: Ongentys (Neurocrine Biosciences)
  • INDICATIONS: Adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes. (Given concomitantly with levodopa/carbidopa).
  • CLASS: Catechol-O-methyl transferase inhibitor
  • HALF-LIFE: 1–2 hours

FDA APPROVAL DATE: 04/24/2020

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Isocarboxazid, Phenelzine, Tranylcypromine


No adequate data on the developmental risk associated with use in pregnant women.

Our database has 13 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
OTHER.


Page last updated 08/01/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top